STAT+: Sarepta demanded Duchenne patient advocacy group censor video critical of the company
STAT
JULY 29, 2024
Sarepta Therapeutics demanded a prominent patient advocacy organization censor a video that contained pointed criticism of the company’s recently approved gene therapy for Duchenne muscular dystrophy, STAT has learned. The incident raises questions about the financial ties between Sarepta and the advocacy group, Parent Project Muscular Dystrophy, and whether the drugmaker uses its money to influence, or even muzzle, debate over its Duchenne medicines.
Let's personalize your content